查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386268

標籤先天性黑蒙市場報告：2030 年趨勢、預測與競爭分析

Leber Congenital Amaurosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

萊伯先天性黑蒙趨勢與預測

到 2030 年，全球標籤先天性黑蒙市場預計將達到 12.6 億美元，2024 年至 2030 年年複合成長率為 4.2%。該市場的主要促進因素是rpe65基因介導的視網膜疾病的盛行率不斷增加、世界各國政府增加LCA研究支出以及製藥公司增加投資。全球標籤先天性黑蒙（LPA）市場的未來前景看好，醫院、專科診所、門診手術中心和家庭醫療保健市場都有商機。

標籤先天性黑蒙市場洞察

Lucintel 預測，由於 LCA 有效治療的需求未得到滿足，該治療將在預測期內出現強勁成長。

醫院將繼續成為該市場中最大的部分，因為它們提供診斷和治療 LCA 所需的設備和專業知識。

由於其發達的醫療基礎設施，預計北美在預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球標籤先天性黑蒙市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球標籤先天性黑蒙市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球標籤先天性黑蒙市場
    • 治療
    • 診斷
  • 按疾病類型分類的全球標籤先天性黑蒙市場
    • 嬰兒型
    • 少年型
    • 其他
  • 按最終用途分類的全球標籤先天性黑蒙市場
    • 醫院
    • 專科診所
    • 門診手術中心
    • 家庭保健
    • 其他
  • 按配銷通路的全球標籤先天性黑蒙市場
    • 直接競標
    • 零售

第4章 2018-2030年分地區市場趨勢及預測分析

  • 按地區分類的全球標籤先天性黑蒙市場
  • 北美標籤先天性黑蒙市場
  • 歐洲標籤先天性黑蒙市場
  • 亞太標籤先天性黑蒙市場
  • 其他地區標籤先天性黑蒙市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球標籤先天性黑蒙市場成長機會（按類型）
    • 全球標籤先天性黑蒙市場成長機會（依疾病類型）
    • 全球標籤先天性黑蒙市場成長機會（依最終用途）
    • 全球標籤先天性黑蒙市場成長機會（按配銷通路）
    • 全球標籤先天性黑蒙市場成長機會（按地區）
  • 全球標籤先天性黑蒙市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球標籤先天性黑蒙市場的容量
    • 全球標籤先天性黑蒙市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN
簡介目錄

Leber Congenital Amaurosis Trends and Forecast

The future of the global leber congenital amaurosis (LPA) market looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets. The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

A more than 150-page report is developed to help in your business decisions.

Leber Congenital Amaurosis by Segment

The study includes a forecast for the global leber congenital amaurosis by type, disease type, end use, distribution channel, and region.

Leber Congenital Amaurosis Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Therapy
  • Diagnosis

Leber Congenital Amaurosis Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Infantile Type
  • Juvenile Type
  • Others

Leber Congenital Amaurosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

Leber Congenital Amaurosis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Retail Sales

Leber Congenital Amaurosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Leber Congenital Amaurosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leber congenital amaurosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leber congenital amaurosis companies profiled in this report include-

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Leber Congenital Amaurosis Market Insights

Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to diagnose and treat LCA.

North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Features of the Global Leber Congenital Amaurosis Market

Market Size Estimates: Leber congenital amaurosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Leber congenital amaurosis market size by various segments, such as by type, disease type, end use, distribution channel, and region in terms of ($B).

Regional Analysis: Leber congenital amaurosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, disease types, end uses, distribution channels, and regions for the leber congenital amaurosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leber congenital amaurosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the leber congenital amaurosis market size?

Answer: The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030.

Q.2 What is the growth forecast for leber congenital amaurosis market?

Answer: The global leber congenital amaurosis market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the leber congenital amaurosis market?

Answer: The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

Q4. What are the major segments for leber congenital amaurosis market?

Answer: The future of the leber congenital amaurosis market (LCA) looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets.

Q5. Who are the key leber congenital amaurosis market companies?

Answer: Some of the key leber congenital amaurosis companies are as follows:

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Q6. Which leber congenital amaurosis market segment will be the largest in future?

Answer: Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Q7. In leber congenital amaurosis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the leber congenital amaurosis market by type (therapy and diagnosis), disease type (infantile type, juvenile type , and others), end use (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others), distribution channel (direct tender and retail sales), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Leber Congenital Amaurosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Leber Congenital Amaurosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Leber Congenital Amaurosis Market by Type
    • 3.3.1: Therapy
    • 3.3.2: Diagnosis
  • 3.4: Global Leber Congenital Amaurosis Market by Disease Type
    • 3.4.1: Infantile Type
    • 3.4.2: Juvenile Type
    • 3.4.3: Others
  • 3.5: Global Leber Congenital Amaurosis Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Home Healthcare
    • 3.5.5: Others
  • 3.6: Global Leber Congenital Amaurosis Market by Distribution Channel
    • 3.6.1: Direct Tender
    • 3.6.2: Retail Sales

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Leber Congenital Amaurosis Market by Region
  • 4.2: North American Leber Congenital Amaurosis Market
    • 4.2.2: North American Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.3: European Leber Congenital Amaurosis Market
    • 4.3.1: European Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.3.2: European Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.4: APAC Leber Congenital Amaurosis Market
    • 4.4.1: APAC Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.4.2: APAC Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.5: ROW Leber Congenital Amaurosis Market
    • 4.5.1: ROW Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.5.2: ROW Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Type
    • 6.1.2: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Leber Congenital Amaurosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Distribution Channel
    • 6.1.5: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Region
  • 6.2: Emerging Trends in the Global Leber Congenital Amaurosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Leber Congenital Amaurosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leber Congenital Amaurosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Invitae Corporation
  • 7.2: Spark Therapeutics
  • 7.3: LKC Technologies
  • 7.4: CENTOGENE
  • 7.5: Optos
  • 7.6: Metrovision
  • 7.7: Blue Print Genetics Oy
  • 7.8: CD Genomics
  • 7.9: ProQR Therapeutics
  • 7.10: OCUGEN